Clostridial toxin derivatives and methods for treating pain
AssigneeAllergan, Inc.
InventorStephen Donovan
Life of this patent
Estimating the term…
Abstract
Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.
Claims28
A method for treating pain in a patient, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an agent to reduce pain, wherein the agent comprises a modified Clostridial toxin comprising,
- a) a Clostridial toxin light chain or fragment thereof that cleaves a neurosecretory protein;
- b) a Clostridial toxin HN domain or fragment thereof that translocates a Clostridial toxin light chain or light chain fragment thereof across an endosome membrane;
- and
- c) a tachykinin polypeptide as a targeting moiety that binds to a tachykinin receptor;
- and
- wherein the HC domain of the modified Clostridial toxin is removed or modified in order to reduce the binding of the modified Clostridial toxin to Clostridial toxin receptors at the neuromuscular junction.
A method for treating pain in a patient, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of an agent, wherein the agent comprises a modified botulinum toxin serotype A comprising,
- a) a botulinum toxin serotype A light chain or fragment thereof that cleaves a neurosecretory protein;
- b) a botulinum toxin serotype A HN domain or fragment thereof that translocates a botulinum toxin serotype A light chain or light chain fragment thereof across an endosome membrane;
- and
- c) a tachykinin polypeptide as a targeting moiety that binds to a tachykinin receptor;
- and
- wherein the HC domain of the modified botulinum toxin serotype A is removed or modified in order to reduce the binding of the modified botulinum toxin serotype A to a botulinum toxin serotype A receptor at the neuromuscular junction.
Dependencies are inferred from the claim text.